
Oncology NEWS International
- Oncology NEWS International Vol 18 No 6
- Volume 18
- Issue 6
A.P. Pharma submits anti-nausea drug for FDA approval
APF530 is undergoing regulatory review for a new drug approval for the prevention of chemotherapy-induced nausea and vomiting, according to manufacturer A.P. Pharma. PF530 is a formulation of granisetron, a 5-HT3 antagonist.
APF530 is undergoing regulatory review for a new drug approval for the prevention of chemotherapy-induced nausea and vomiting, according to manufacturer A.P. Pharma. PF530 is a formulation of granisetron, a 5-HT3 antagonist.
The drug is delivered using the company’s Biochronomer system, which allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection.
In a phase III, randomized, multicenter trial of 1,395 cancer patients, APF530 was shown to be as effective as palonosetron (Aloxi) for the prevention of acute onset and delayed onset CINV, A.P. Pharma said in a statement.
Articles in this issue
almost 17 years ago
ADT in prostate ca increases risk of bone and heart complicationsalmost 17 years ago
Abraxis backs SPARC as prognostic biomarkeralmost 17 years ago
ALK-1 receptor: New target in angiogenesisalmost 17 years ago
Abraxane prolongs PFS in metastatic diseasealmost 17 years ago
SAVI applicator removes obstacles associated with brachytherapyalmost 17 years ago
Mistrust, costs reduce breast cancer screening among minoritiesalmost 17 years ago
Oral chemotherapy poses more challenges for cancer communityalmost 17 years ago
CMS nixes CT colonography screeningalmost 17 years ago
New ultrasound strategy helps pinpoint prostate tumorsNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.























































